Symbols / VIVS $1.80 +0.00%
VIVS Chart
About
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.69M |
| Enterprise Value | 1.22M | Income | -1.23M | Sales | 142.00K |
| Book/sh | 1.70 | Cash/sh | 1.64 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | 1.02 | Forward P/E | — | PEG | — |
| P/S | 33.06 | P/B | 1.06 | P/C | — |
| EV/EBITDA | -0.11 | EV/Sales | 8.58 | Quick Ratio | 1.75 |
| Current Ratio | 2.44 | Debt/Eq | 18.28 | LT Debt/Eq | — |
| EPS (ttm) | 1.76 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 8.30% | Earnings | 2025-02-19 09:00 | ROA | -132.52% |
| ROE | -51.07% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -105.77% | Profit Margin | 0.00% | Shs Outstand | 2.61M |
| Shs Float | 2.58M | Short Float | 1.27% | Short Ratio | 0.01 |
| Short Interest | — | 52W High | 5.30 | 52W Low | 1.41 |
| Beta | 1.32 | Avg Volume | 1.73M | Volume | 26.31K |
| Target Price | — | Recom | None | Prev Close | $1.80 |
| Price | $1.80 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.80
Latest analyst target
3. DCF / Fair value
$-54.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.80
Low
—
High
—
Mean
—
- Why Is VIVS Stock Up 79% Today? - Stocktwits Fri, 30 Jan 2026 08
- Boston-based PhD executive to lead global sales at tox-tech firm VivoSim - Stock Titan ue, 03 Mar 2026 08
- $VIVS stock is up 71% today. Here's what we see in our data. - Quiver Quantitative Fri, 30 Jan 2026 08
- VIVS Stock Price and Chart — NASDAQ:VIVS - TradingView hu, 24 Apr 2025 12
- Is VivoSim Labs Stock a Hidden Gem? - StocksToTrade hu, 30 Oct 2025 07
- VivoSim Labs stock (VIVS) jumps premarket after Korea, China distributor deals — what to watch next - TechStock² Fri, 30 Jan 2026 08
- VivoSim Labs, Inc. - Common Stock (NQ: VIVS - The Chronicle-Journal Fri, 30 Jan 2026 20
- Morning Market Movers: TCGL, VIVS, LRHC, KXIN See Big Swings - RTTNews Fri, 30 Jan 2026 08
- Human-based liver toxicology tests head to Korea and China in 30 days - Stock Titan hu, 29 Jan 2026 08
- VivoSim Labs Stock Soars After Major Distribution Deals in Asia - timothysykes.com Sat, 31 Jan 2026 08
- 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga Fri, 30 Jan 2026 08
- Vivendi (ENXTPA:VIV): Exploring the Valuation Narrative Behind Recent Share Price Fluctuations - simplywall.st ue, 09 Sep 2025 07
- VivoSim Labs Leaps 82% Amid Strategic Partnerships in Asia - StocksToTrade Sun, 01 Feb 2026 08
- VIVS Stock Price, News & Analysis - Stock Titan Sat, 26 Apr 2025 03
- VivoSim Labs Shares Surge 82% Amid Key Asia Distribution Deals - StocksToTrade Sat, 31 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | STERN ADAM K. | Director | — | 2026-01-27 00:00:00 | D |
| 1 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | MURPHY KEITH E | Officer and Director | — | 2026-01-27 00:00:00 | D |
| 2 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | GOBEL DAVID | Director | — | 2026-01-27 00:00:00 | D |
| 3 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | COHEN DOUGLAS JAY | Director | — | 2026-01-27 00:00:00 | D |
| 4 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | MILHOUS ALISON TJOSVOLD | Director | — | 2026-01-27 00:00:00 | D |
| 5 | 19607 | — | — | Stock Award(Grant) at price 0.00 per share. | STERN ADAM K. | Director | — | 2024-08-07 00:00:00 | D |
| 6 | 19607 | — | — | Stock Award(Grant) at price 0.00 per share. | MURPHY KEITH E | Officer and Director | — | 2024-08-07 00:00:00 | D |
| 7 | 19607 | — | — | Stock Award(Grant) at price 0.00 per share. | GOBEL DAVID | Director | — | 2024-08-07 00:00:00 | D |
| 8 | 19607 | — | — | Stock Award(Grant) at price 0.00 per share. | COHEN DOUGLAS JAY | Director | — | 2024-08-07 00:00:00 | D |
| 9 | 19607 | — | — | Stock Award(Grant) at price 0.00 per share. | MILHOUS ALISON TJOSVOLD | Director | — | 2024-08-07 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 2.10M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.21 |
| NormalizedEBITDA | -12.21M | -14.40M | -17.46M | -11.34M |
| TotalUnusualItems | 10.00M | 12.00K | 20.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 10.00M | 12.00K | 20.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.49M | -14.67M | -17.26M | -11.45M |
| ReconciledDepreciation | 266.00K | 280.00K | 293.00K | 142.00K |
| ReconciledCostOfRevenue | 5.00K | 0.00 | 0.00 | |
| EBITDA | -2.21M | -14.39M | -17.44M | -11.34M |
| EBIT | -2.48M | -14.67M | -17.73M | -11.48M |
| NetInterestIncome | 130.00K | 405.00K | 454.00K | 8.00K |
| InterestExpense | 10.00K | 0.00 | ||
| InterestIncome | 140.00K | 405.00K | 454.00K | 8.00K |
| NormalizedIncome | -10.39M | -14.68M | -17.28M | -11.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.49M | -14.67M | -17.26M | -11.45M |
| TotalExpenses | 12.76M | 15.20M | 18.10M | 12.98M |
| TotalOperatingIncomeAsReported | -12.62M | -15.09M | -17.73M | -11.48M |
| DilutedAverageShares | 1.46M | 762.08K | 726.09K | 725.30K |
| BasicAverageShares | 1.46M | 762.08K | 726.09K | 725.30K |
| DilutedEPS | -1.70 | -19.25 | -23.76 | -15.84 |
| BasicEPS | -1.70 | -19.25 | -23.76 | -15.84 |
| DilutedNIAvailtoComStockholders | -2.49M | -14.67M | -17.26M | -11.45M |
| NetIncomeCommonStockholders | -2.49M | -14.67M | -17.26M | -11.45M |
| NetIncome | -2.49M | -14.67M | -17.26M | -11.45M |
| NetIncomeIncludingNoncontrollingInterests | -2.49M | -14.67M | -17.26M | -11.45M |
| NetIncomeContinuousOperations | -2.49M | -14.67M | -17.26M | -11.45M |
| TaxProvision | 2.00K | 2.00K | 2.00K | 2.00K |
| PretaxIncome | -2.49M | -14.67M | -17.26M | -11.45M |
| OtherIncomeExpense | 10.00M | 12.00K | 20.00K | 25.00K |
| OtherNonOperatingIncomeExpenses | 25.00K | 6.00K | ||
| SpecialIncomeCharges | 10.00M | 0.00 | -9.00K | 0.00 |
| GainOnSaleOfPPE | 10.00M | 0.00 | -9.00K | 0.00 |
| GainOnSaleOfSecurity | 12.00K | 29.00K | ||
| NetNonOperatingInterestIncomeExpense | 130.00K | 405.00K | 454.00K | 8.00K |
| InterestExpenseNonOperating | 10.00K | 0.00 | ||
| InterestIncomeNonOperating | 140.00K | 405.00K | 454.00K | 8.00K |
| OperatingIncome | -12.62M | -15.09M | -17.73M | -11.48M |
| OperatingExpense | 12.76M | 15.20M | 18.10M | 12.98M |
| DepreciationAmortizationDepletionIncomeStatement | 39.00K | 53.00K | 128.00K | 28.00K |
| DepreciationAndAmortizationInIncomeStatement | 39.00K | 53.00K | 128.00K | 28.00K |
| ResearchAndDevelopment | 5.03M | 5.50M | 8.88M | 3.32M |
| SellingGeneralAndAdministration | 7.69M | 9.64M | 9.09M | 9.63M |
| GeneralAndAdministrativeExpense | 7.69M | 9.64M | 9.09M | 9.63M |
| OtherGandA | 7.25M | 8.27M | 7.18M | 7.79M |
| SalariesAndWages | 446.00K | 1.37M | 1.90M | 1.84M |
| GrossProfit | 139.00K | 109.00K | 0.00 | |
| CostOfRevenue | 5.00K | 0.00 | 0.00 | |
| TotalRevenue | 144.00K | 109.00K | 370.00K | 1.50M |
| OperatingRevenue | 144.00K | 109.00K | 370.00K | 1.50M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 3.00 | 3.00 | 3.00 | 3.00 |
| OrdinarySharesNumber | 1.90M | 839.81K | 726.41K | 725.88K |
| ShareIssued | 1.90M | 839.81K | 726.41K | 725.89K |
| TotalDebt | 942.00K | 1.39M | 1.80M | 2.18M |
| TangibleBookValue | 10.49M | 3.60M | 15.33M | 30.21M |
| InvestedCapital | 10.49M | 3.60M | 15.33M | 30.21M |
| WorkingCapital | 8.39M | 2.08M | 13.38M | 28.15M |
| NetTangibleAssets | 10.49M | 3.60M | 15.33M | 30.21M |
| CapitalLeaseObligations | 942.00K | 1.39M | 1.80M | 2.18M |
| CommonStockEquity | 10.49M | 3.60M | 15.33M | 30.21M |
| TotalCapitalization | 10.49M | 3.60M | 15.33M | 30.21M |
| TotalEquityGrossMinorityInterest | 10.49M | 3.60M | 15.33M | 30.21M |
| StockholdersEquity | 10.49M | 3.60M | 15.33M | 30.21M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 2.00K | 0.00 | |
| OtherEquityAdjustments | 2.00K | |||
| TreasuryStock | 1.00K | 1.00K | 1.00K | 1.00K |
| RetainedEarnings | -342.16M | -339.67M | -325.00M | -307.74M |
| AdditionalPaidInCapital | 352.65M | 343.27M | 340.32M | 337.94M |
| CapitalStock | 2.00K | 1.00K | 9.00K | 9.00K |
| CommonStock | 2.00K | 1.00K | 9.00K | 9.00K |
| TotalLiabilitiesNetMinorityInterest | 4.16M | 2.75M | 4.98M | 3.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 421.00K | 888.00K | 1.31M | 1.70M |
| LongTermDebtAndCapitalLeaseObligation | 421.00K | 888.00K | 1.31M | 1.70M |
| LongTermCapitalLeaseObligation | 421.00K | 888.00K | 1.31M | 1.70M |
| CurrentLiabilities | 3.74M | 1.86M | 3.67M | 1.38M |
| OtherCurrentLiabilities | 346.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 521.00K | 506.00K | 492.00K | 479.00K |
| CurrentCapitalLeaseObligation | 521.00K | 506.00K | 492.00K | 479.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 652.00K | 536.00K | 609.00K | 434.00K |
| PayablesAndAccruedExpenses | 2.22M | 818.00K | 2.57M | 470.00K |
| CurrentAccruedExpenses | 574.00K | 191.00K | 2.24M | 55.00K |
| Payables | 1.64M | 627.00K | 331.00K | 415.00K |
| AccountsPayable | 1.64M | 627.00K | 331.00K | 415.00K |
| TotalAssets | 14.65M | 6.35M | 20.31M | 33.30M |
| TotalNonCurrentAssets | 2.52M | 2.41M | 3.27M | 3.76M |
| OtherNonCurrentAssets | 1.23M | 445.00K | 658.00K | 948.00K |
| NonCurrentPrepaidAssets | 805.00K | 1.03M | ||
| NetPPE | 1.29M | 1.97M | 2.61M | 2.81M |
| AccumulatedDepreciation | -1.52M | -1.26M | -1.28M | -1.07M |
| GrossPPE | 2.81M | 3.23M | 3.88M | 3.89M |
| OtherProperties | 1.63M | 1.62M | 1.57M | 1.17M |
| MachineryFurnitureEquipment | 310.00K | 310.00K | 603.00K | 562.00K |
| BuildingsAndImprovements | 867.00K | 1.30M | 1.71M | 2.15M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 12.13M | 3.94M | 17.05M | 29.53M |
| OtherCurrentAssets | 12.00K | 4.00K | 69.00K | 858.00K |
| PrepaidAssets | 777.00K | 701.00K | 820.00K | 858.00K |
| Inventory | 0.00 | 297.00K | 0.00 | |
| FinishedGoods | 0.00 | 297.00K | 0.00 | |
| Receivables | 30.00K | 33.00K | 152.00K | 0.00 |
| AccountsReceivable | 30.00K | 33.00K | 152.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 11.31M | 2.90M | 16.01M | 28.68M |
| OtherShortTermInvestments | 0.00 | 706.00K | 0.00 | |
| CashAndCashEquivalents | 11.31M | 2.90M | 15.30M | 28.68M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.47M | -14.70M | -12.80M | -8.86M |
| RepurchaseOfCapitalStock | 0.00 | -1.00K | ||
| IssuanceOfCapitalStock | 8.85M | 1.44M | 0.00 | 251.00K |
| CapitalExpenditure | -13.00K | -42.00K | -396.00K | -409.00K |
| InterestPaidSupplementalData | 10.00K | 0.00 | ||
| IncomeTaxPaidSupplementalData | 2.00K | 2.00K | 2.00K | 2.00K |
| EndCashPosition | 11.46M | 3.04M | 15.44M | 28.82M |
| BeginningCashPosition | 3.04M | 15.44M | 28.82M | 37.48M |
| ChangesInCash | 8.41M | -12.40M | -13.37M | -8.66M |
| FinancingCashFlow | 8.85M | 1.44M | 0.00 | 205.00K |
| CashFlowFromContinuingFinancingActivities | 8.85M | 1.44M | 0.00 | 205.00K |
| NetOtherFinancingCharges | -46.00K | -4.00K | ||
| ProceedsFromStockOptionExercised | 0.00 | 42.00K | ||
| NetCommonStockIssuance | 8.85M | 1.44M | 0.00 | 251.00K |
| CommonStockPayments | 0.00 | -1.00K | ||
| CommonStockIssuance | 8.85M | 1.44M | 0.00 | 251.00K |
| InvestingCashFlow | 9.03M | 816.00K | -966.00K | -409.00K |
| CashFlowFromContinuingInvestingActivities | 9.03M | 816.00K | -966.00K | -409.00K |
| NetInvestmentPurchaseAndSale | 38.00K | 858.00K | -570.00K | 0.00 |
| SaleOfInvestment | 3.00M | 11.72M | 10.38M | 0.00 |
| PurchaseOfInvestment | -2.96M | -10.86M | -10.95M | 0.00 |
| NetPPEPurchaseAndSale | 8.99M | -42.00K | -396.00K | -409.00K |
| SaleOfPPE | 9.00M | 0.00 | 0.00 | 12.00K |
| PurchaseOfPPE | -13.00K | -42.00K | -396.00K | -409.00K |
| OperatingCashFlow | -9.46M | -14.65M | -12.41M | -8.45M |
| CashFlowFromContinuingOperatingActivities | -9.46M | -14.65M | -12.41M | -8.45M |
| ChangeInWorkingCapital | 1.04M | -2.02M | 2.31M | 597.00K |
| ChangeInOtherWorkingCapital | -5.00K | 70.00K | 30.00K | |
| ChangeInOtherCurrentLiabilities | -452.00K | -411.00K | ||
| ChangeInPayablesAndAccruedExpense | 1.73M | -1.82M | 2.21M | 183.00K |
| ChangeInAccruedExpense | 717.00K | -2.12M | 2.36M | 49.00K |
| ChangeInPayable | 1.02M | 296.00K | -148.00K | 134.00K |
| ChangeInAccountPayable | 1.02M | 296.00K | -148.00K | 134.00K |
| ChangeInPrepaidAssets | 253.00K | 392.00K | 177.00K | 384.00K |
| ChangeInInventory | -501.00K | -297.00K | 0.00 | 0.00 |
| ChangeInReceivables | 3.00K | 119.00K | -152.00K | 0.00 |
| ChangesInAccountReceivables | 3.00K | 119.00K | -152.00K | 0.00 |
| OtherNonCashItems | 432.00K | 406.00K | ||
| StockBasedCompensation | 532.00K | 1.51M | 2.38M | 2.26M |
| AssetImpairmentCharge | 798.00K | 0.00 | 0.00 | |
| AmortizationOfSecurities | -38.00K | -142.00K | -105.00K | 0.00 |
| DepreciationAmortizationDepletion | 266.00K | 280.00K | 293.00K | 142.00K |
| DepreciationAndAmortization | 266.00K | 280.00K | 293.00K | 142.00K |
| OperatingGainsLosses | -10.00M | -12.00K | -20.00K | 19.00K |
| EarningsLossesFromEquityInvestments | 0.00 | -12.00K | -29.00K | 0.00 |
| GainLossOnSaleOfPPE | 0.00 | 9.00K | 0.00 | 19.00K |
| NetIncomeFromContinuingOperations | -2.49M | -14.67M | -17.26M | -11.45M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VIVS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|